# The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD

> clinical trial · VERIFIED · 2026-08-20

Status: RECRUITING · Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Condition: Systemic Lupus Erythematosus

- Company: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Sector: therapeutics
- Primary source: https://clinicaltrials.gov/study/NCT05440422

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.